Hepatitis C Diagnosis and Treatment Market Research Report - Global Forecast till 2027

Hepatitis C Diagnosis and Treatment Market Size, Trends and Growth Analysis By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/MED/1040-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill Sample form for the updated data.

Hepatitis C Diagnosis and Treatment Market Scenario


Hepatitis C Diagnosis and Treatment Market is expected to exhibit significant growth over the forecast period. The market is projected to register a 3.82% CAGR over the forecast period.


Hepatitis C is a liver infection that is caused due to the hepatitis C virus. The hepatitis C virus may cause both acute as well as chronic hepatitis. It is a bloodborne virus and is commonly infected through small quantities of blood.


Factors such as the high prevalence of hepatitis C and increasing awareness regarding the disease are expected to drive the market growth. According to an article published by the World Health Organization (WHO) in July 2019, an estimated 71 million people suffer from chronic hepatitis C virus infection, globally.


However, stringent government regulations and alternate treatment options, such as herbal treatment offered at comparatively lower prices are expected to hamper the Hepatitis C Diagnosis and Treatment Market growth.


Key Players


Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), Gilead Sciences, Inc. (US), AbbVie Inc. (US), GlaxoSmithKline PLC (UK), Novartis Pharmaceuticals Corporation (Switzerland), Bristol-Myers Squibb Company (US), Abbott (US), Beckman Coulter, Inc. (US), Siemens Medical Solutions USA, Inc. (Germany), MedMira Inc. (Canada), DiaSorin SpA (Italy), Qiagen (Germany), bioMérieux SA (France), Hologic, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are some of the Key Players operating in the Global Hepatitis C Diagnosis and Treatment Market.


Segmentation


The Hepatitis C Diagnosis and Treatment Market has been segmented into diagnosis, treatment, end-user, and region.


Based on diagnosis, the global market has been divided into liver function tests, liver biopsy, blood tests, and others.


The global market, by treatment, has been segmented into antiviral medications, immune-modulators, liver transplantation, and others.


The global hepatitis C diagnosis and treatment market, by end-user, has been segmented into hospitals & clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 


The hepatitis C diagnosis and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The Middle East & Africa market has been segmented into the Middle East and Africa.


Regional Market Summary


Global Hepatitis C Diagnosis and Treatment Market Share (%), by Region, 2018  Hepatitis C Diagnosis and Treatment Market


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the hepatitis C diagnosis and treatment market owing to the increasing patient population suffering from hepatitis C and presence of major players, such as Vertex Pharmaceuticals Incorporated, AbbVie Inc., Bristol-Myers Squibb Company, Abbott, Beckman Coulter, Inc., Hologic, Inc., and Bio-Rad Laboratories, Inc. in the region. According to a report published by the Centers for Disease Control and Prevention in July 2019, approximately 2.4 million people in the US are suffering from hepatitis C.


Europe is expected to hold the second-largest position in the global market owing to the growing awareness regarding hepatitis C and the rising patient population suffering from the disease. According to the WHO, as of 2018, 14 million people in Europe suffered from hepatitis C.


Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from hepatitis C and rising number of initiatives taken by governments as well as private institutes to create awareness regarding hepatitis C. For instance, In June 2015, Abbott launched “LiverHealth”, an initiative to provide easy diagnosis of liver health and to raise awareness regarding hepatitis C in India.


The hepatitis C diagnosis and treatment market in the Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from hepatitis C. According to the WHO, 10 million people in Africa suffer from chronic viral hepatitis C.


Global Hepatitis C Diagnosis and Treatment Market, by Diagnosis



  • Liver Function Tests

  • Liver Biopsy

  • Blood Tests

  • Others


Global Hepatitis C Diagnosis and Treatment Market, by Treatment



  • Antiviral Medications

  • Immuno-Modulators

  • Liver Transplantation

  • Others


Global Market, by End User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Others


Global Hepatitis C Diagnosis and Treatment Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Biotechnology and Pharmaceutical Companies

  • Research Institutes

  • Medical Device Companies

  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Academic Institutes

  • Government Organizations



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   3.82% (2019-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Diagnosis, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), Gilead Sciences, Inc. (US), AbbVie Inc. (US), GlaxoSmithKline PLC (UK), Novartis Pharmaceuticals Corporation (Switzerland), Bristol-Myers Squibb Company (US), Abbott (US), Beckman Coulter, Inc. (US), Siemens Medical Solutions USA, Inc. (Germany), MedMira Inc. (Canada), DiaSorin SpA (Italy), Qiagen (Germany), bioMérieux SA (France), Hologic, Inc. (US), and Bio-Rad Laboratories, Inc. (US)
  Key Market Opportunities

  • The Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from hepatitis C. \r\n
  • According to the WHO, 10 million people in Africa suffer from chronic viral hepatitis C
  •   Key Market Drivers   Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from hepatitis C and rising number of initiatives taken by governments as well as private institutes to create awareness regarding hepatitis C


    Frequently Asked Questions (FAQ) :


    Hepatitis C diagnosis and treatment market is projected to grow at approximately 3.82% CAGR during the assessment period (2019-2025).

    high prevalence and increasing awareness about the diseases are major tailwinds pushing the growth of the global Hepatitis C diagnosis and treatment market.

    Stringent government regulations and the availability of alternate treatment options are major growth impeders for the global Hepatitis C diagnosis and treatment market.

    North America holds the largest share in the global Hepatitis C diagnosis and treatment market, followed by Europe and the Asia Pacific, respectively.

    Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), Vertex Pharmaceuticals Incorporated (US), AbbVie Inc. (US), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline PLC (UK), Bristol-Myers Squibb Company (US), Beckman Coulter, Inc. (US), Abbott (US), Siemens Medical Solutions USA, Inc. (Germany), DiaSorin SpA (Italy), MedMira Inc. (Canada), Qiagen (Germany), Hologic, Inc. (US), bioMérieux SA (France), and Bio-Rad Laboratories, Inc. (US), are some of the top players operating in the global Hepatitis C diagnosis and treatment market.